CTLA4 and melanoma: Moreover, for BRAF wild-type melanomas, current recommendations advocate using monoclonal antibodies (i.e., ipilimumab) that target immunological checkpoint proteins such as anti-PD-1 or CTLA-4 (cytotoxic T-lymphocyte antigen 4) in combination with anti-PD-1 therapy [69].